Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CR-1 is a near-infrared-II (NIR-II) croconaine dye that serves as a pH-sensitive theranostic agent. In the context of oncology, particularly hepatocellular carcinoma (HCC), CR-1 is utilized as the core imaging and therapeutic component of smart nanoprobes, such as the self-assembling CR-PEG-GBP conjugate. This molecule is designed to respond to the acidic tumor microenvironment (pH ~6.5), where it undergoes in situ self-assembly from small nanoprobes into larger nanoparticles. This aggregation enhances its tumor accumulation and retention time while facilitating dual-modal imaging (NIR-II fluorescence and photoacoustic imaging) and dual-modal therapy, including photothermal therapy (PTT) and sonodynamic therapy (SDT). By generating heat and reactive oxygen species (ROS) upon activation by light or ultrasound, CR-1 provides a targeted approach to tumor ablation with high detection sensitivity and deep tissue penetration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CR-1.